Ildong Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 16, 2022 at 02:46 am
Share
Ildong Holdings Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was KRW 3,185.74 million compared to KRW 2,160.07 million a year ago. Net loss was KRW 54,760.05 million compared to KRW 13,445.22 million a year ago. Basic loss per share from continuing operations was KRW 4,849 compared to KRW 1,191 a year ago. Basic loss per share was KRW 4,849 compared to KRW 1,191 a year ago.
Ildong Holdings Co., Ltd., formerly Ildong Pharmaceuticals Co., Ltd., is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products mainly include general drugs and specialty drugs, such as vitamin supplements, digestive medications, vascular medications, probiotics, topical applications, anti-histamines, antipyretics, analgesics, respiratory medications, endocrine medications, psychoneurological medications, dermatological medications, urologic medications, antibiotics and others. It also provides raw materials, such as synthesises, probiotics and others. In addition, through its subsidiaries, it engages in the advertising agency, medical equipment distribution, software development, food processing and other businesses.